Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy
Sage is representing Mateon Therapeutics, a US-based biopharma company focusing on Vascular Disrupting Agents (VDAs) for orphan oncology indications. The company has two VDAs in clinical development, CA4P and OXi4503, the lead one of which is being studied in a phase 2/3 clinical trial in platinum resistant ovarian cancer. Similar to anti-angiogenic agents (AAs), which have been FDA approved and are widely used in cancer treatment, VDAs work by interfering with a tumor’s bloo